IPSC — Century Therapeutics Share News
0.000.00%
Last trade - 00:00- $264.37m
- $144.66m
- $109.16m
Brief: Sagimet Biosciences Announces Appointment Of Tim Walbert And Paul Hoelscher To Board Of Directors
Brief: Century Therapeutics Reports Full Year 2023 Financial Results
Brief: Century Therapeutics Sees FY operating expenses USD 135-145 million
Brief: Century Therapeutics CFO Michael Diem To Resign
Brief: Century Therapeutics Presents Initial Data From Cnty-101 Phase 1 Elipse-1 Trial Supporting The Potential For A Multi-Dosing Strategy For Car Ink Enabled By Allo-Evasion Edits
Brief: Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
CAR-T therapy developers fall amid U.S. FDA investigation
Brief: Century Therapeutics Board Appointed Brent Pfeiffenberger To Serve As Chief Executive Officer
Brief: Century Therapeutics Reports Third Quarter 2023 Financial Results And Provides Business Updates
Brief: Century Therapeutics Appoints Brent Pfeiffenberger As Chief Executive Officer
Brief: Century And Fujifilm Announce Licenses For Development And Commercialization Of IPSC-Derived Cell Therapies In Autoimmune And Inflammatory Diseases
U.S. RESEARCH ROUNDUP-Intuit, Pioneer Natural Resources, Salesforce
U.S. RESEARCH ROUNDUP-Penn Entertainment, Roblox, Sonendo
Brief: Century Therapeutics Reports Q1 2023 Financial Results And Provides Business Updates
Brief: Century Therapeutics Q1 EPS USD -0.53
Brief: Century Therapeutics Inc Board Reduced Its Size To Seven Members
U.S. STOCKS ON THE MOVE-SiriusPoint, Nutex Health, Barrick Gold
U.S. STOCKS ON THE MOVE-SiriusPoint, Shopify, Gold miners
Century Therapeutics CEO Lalo Flores steps down, shares fall